Heparin disaccharides inhibit tumor necrosis factor-α production by macrophages and arrest immune inflammation in rodents

International Immunology

Volumn 9, Issue 10, 1997, Pages 1517-1522

  Cahalon, Liora ^a   Lider, Ofer ^a   Schor, Hagai ^a   Avron, Ann ^a   Gilat, Dalia ^a   Hershkoviz, Rami ^a   Margalit, Raanan ^a   Eshel, Adi ^b   Shoseyev, Oded ^b   Cohen, Irun R ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Arthritis; Cytokines; Lymphocytes; Oligosaccharides

Indexed keywords

DISACCHARIDE; HEPARIN; HEPARIN LYASE; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; FEMALE; IMMUNOPATHOLOGY; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN SENSITIZATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; DISACCHARIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPARIN; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; INFLAMMATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RATS; RATS, INBRED LEW; TUMOR NECROSIS FACTOR-ALPHA;

EID: 9844220845     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/9.10.1517     Document Type: Article

References (21)

1. Kjellen, L. and Lindahl, U. 1991. Proteoglycans: structures and interactions. Annu. Rev. Biochem. 60:443.
2. Ishai-Michaeli, R., Svahn, C. M., Weber, M., Chajek-Shaul, T., Korner, G., Ekre, H.-P. and Vlodavsky, I. 1992. Importance of size and sulfation of heparin in release of bFGF from the vascular endothelium and extracellular matrix. Biochemistry 31:2080.
3. Hahnenberger, R., Jakobson, A. M., Ansari, A., Wehler, T., Svahn. C. M. and Lindahl, U. 1993. Low sulfated oligosaccharides derived from heparan sulfate inhibit normal angiogenesis. Glycobiology 3:567.
4. Nelson, R. M., Cecconi, O., Roberts, W. G., Aruffo, A., Linhardt, R. J. and Bevilacqua, M. P. 1993. Heparin oligosaccharides bind L-selectin and P-selectin and inhibit acute inflammation. Blood 82:3253.
5. Lider, O., Baharav, E., Mekori, Y. A., Miller, T., Naparstek, Y., Vlodavsky, I. and Cohen, I. R. 1989. Suppression of experimental autoimmune diseases and prolongation of allograft survival with heparinoid inhibitors of T lymphocyte heparanase. J. Clin. Invest. 83:752.
6. Lider, O., Mekori, Y. A., Miller, T., Bar-Tana, R., Vlodavsky, I., Baharav, E., Cohen, I. R. and Naparstek. Y. 1990. Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur. J. Immunol. 20:493.
7. Gilat, D., Hershkoviz, R., Cahalon, L., Goldkorn, I., Korner, G., Vlodavsky, I. and Lider, O. 1995. Molecular behavior adapts to context: heparanase functions as an extracellular matrix degrading enzyme or as a T cell adhesion molecule depending on the local pH. J. Exp. Med. 181:1929.
8. Lider, O., Cahalon, L., Gilat, D., Hershkoviz, R., Seigel, D., Margalit, R., Shoseyev, O. and Cohen, I. R. 1995. A disaccharide that inhibits tumor necrosis factor-α is formed from the extracellular matrix by the enzyme heparanase. Proc. Natl Acad. Sci. USA 92:5037.
9. Hopewood, J. J. 1989. Enzymes that degrade heparin and heparan sulfate. In Lane, D. A. and Lindahl, U., eds, Heparin. Chemical and Biological Properties, Clinical Applications, p. 191. Edward Arnold, London.
10. Rice, K. G., Kim, Y. S., Grant, A. C., Merchant, Z. M. and Linhardt, R. J. 1985. High- performance liquid Chromatographic separation of heparin-derived oligosaccharides. Anal. Biochem. 150:325.
11. Ampofo, S. A., Wang, H. M. and Linhardt, R. J. 1991. Disaccharide compositional analysis of heparin and heparan sulfate using capillary zone electrophoresis. Anal. Biochem. 199:249.
12. Desai, U. R., Wang, H. M. and Linhardt, R. J. 1993. Substrate specificity of the lyases from Flavobacterium heparinum. Arch. Biochem. Biophys. 306:461.
13. Tyrell, D. J., Kilfeather, S. and Page, C. P. 1995. Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol. Sci. 16:198.
14. Nieduszynski, I. 1989. General physical properties of heparin. In Lane, D. A. and Lindahl, U., eds, Heparin. Chemical and Biological Properties, Clinical Applications, p. 51. Edward Arnold, London.
15. Nader, H. B. and Dietrich, C. P. 1989. Natural occurrence and possible biologic role of heparin. In Lane, D. A. and Lindahl, U., eds, Heparin, Chemical and Biological Properties, Clinical Applications, p. 81. Edward Arnold, London.
16. Wrenshall, L. E., Cerra, F. B., Singh, R. K. and Platt, J. L. 1995. Heparan sulfate initiates signals in murine macrophages leading to divergent biologic outcomes. J. Immunol. 154:871.
17. Parish, C. R., Bradbury, M. G., Weston, S. A. and Warren, H. S. 1992. Carbohydrate recognition molecules on lymphocytes. Biochem. Soc. Trans. 20:295.
18. Lindahl, U., Bäckström, G., Höök, M., Thunberg, L., Fransson, L. A. and Linker. A. 1979. Structure of anti-thrombin binding site in heparin. Proc. Natl Acad. Sci. USA 76:3198.
19. Desai, U. R., Wang, H. M., Ampofo, S. A. and Linhardt, R. J. 1993. Oligosaccharide composition of heparin and low molecular weight heparins by capillary electrophoresis. Anal. Biochem. 213:120.
20. Linhardt, R. J., Turnbull, J. E., Wang, H. M., Loganathan, D. and Gallagher, J. T. 1990. Examination of the substrate specificity of heparin and heparan sulfate lyases. Biochemistry 29:2611.
21. Bezouska, K, Yuen, C. T., O'Brien, J., Childs, R. A., Chai, W., Lawson, A. M., Drbal, K., Fiserova, A., Pospisil, M. and Feizi. T. 1994. Oligosaccharide ligands for NKR-P1 protein activate NK cells and cytotoxicity. Nature 372:150.